Form 4 Filing for Coherus Oncology, Inc.

This filing details transactions by Ali J. Satvat, a director at Coherus Oncology, Inc. On June 5, 2026, Satvat acquired 30,000 shares of Common Stock and was granted 60,000 stock options. The Common Stock acquisition, valued at $0 per share, is marked under footnote F1, indicating they are restricted stock units (RSUs) that will vest one year after June 3, 2026, contingent on continued service. The stock options, also valued at $0 per share, are exercisable for 60,000 shares of Common Stock and will vest on June 3, 2027, subject to continued service. The exercise price for these options is $1.45 per share. These transactions are reported on Form 4, indicating changes in beneficial ownership.